A Phase 2, Randomized, Crossover Study to Evaluate the Effect of Intranasal Insulin and NovoLog on Postprandial Glycemic Control in Type 2 Diabetic Patients
Latest Information Update: 09 Jul 2019
At a glance
- Drugs Insulin (Primary) ; Insulin aspart
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics; Therapeutic Use
- Sponsors Adhera Therapeutics
- 09 Oct 2018 According to an Adhera Therapeutics media release, the company has changed its name from Marina Biotech to Adhera Therapeutics.
- 10 Jun 2008 Primary endpoint met; results were reported at the 68th Scientific Sessions of the American Diabetes Association according to a Nastech Pharmaceutical media release.
- 10 Jun 2008 Status changed from in progress to completed according to Nastech Pharmaceutical Company.